IMBRAVE050-UPDATED

NCT04102098 📎

Regimen

Experimental
adjuvant atezolizumab + bevacizumab x 12 months
Control
active surveillance

Population

High-risk hepatocellular carcinoma after curative-intent resection or ablation (updated analysis)

Key finding

Updated RFS HR 0.90 (95% CI 0.72-1.12) — benefit NOT sustained; OS HR 1.26 (95% CI 0.85-1.87) trending adverse. Initial positive readout (HR 0.72) reverted with maturity. Indication withdrawn 2024.

Source: PMID 41580093

Timeline

    Guideline citations

    • NCCN HCC (p.50)